Investigational drug · Phase 3
zovaglutide
Also called: ZT002
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight , Obesity, Overweight or Obesity.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
5
Any phase or sponsor naming "zovaglutide"
First trial start
2024
Aug 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "zovaglutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight , Obesity
- Overweight or Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "zovaglutide" as an intervention, largest first.
- A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)Pivotal-lookingActive, not recruiting
Beijing QL Biopharmaceutical Co.,LtdIndustry
NCT07230119 · 755 participants · Start Jan 16, 2026 · Primary completion May 29, 2027
Drug: Zovaglutide dose 1; Zovaglutide dose 2 and 1 more · For: Overweight , Obesity
Sites: Xuancheng, China; Beijing, China; Chongqing, China · 45 sites in all
- A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)Pivotal-lookingNot yet recruiting
Beijing QL Biopharmaceutical Co.,LtdIndustry
NCT07812597 · 210 participants (planned) · Start Oct 12, 2026 · Primary completion Jan 13, 2028
Drug: zovaglutide Arm 1; zovaglutide Arm 2 and 1 more · For: Obesity
Sites: Beijing, China; Huizhou, China; Handan, China · 16 sites in all
- A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy ParticipantsActive, not recruiting
Beijing QL Biopharmaceutical Co.,LtdIndustry
NCT07443059 · 40 participants (planned) · Start Apr 13, 2026 · Primary completion Dec 3, 2026
Drug: Zovaglutide; Zovaglutide and 2 more · For: Overweight , Obesity
Sites: Xiamen, China; Jinan, China; Chengdu, China
- A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy AdultsActive, not recruiting
Beijing QL Biopharmaceutical Co.,LtdIndustry
NCT07697846 · 40 participants (planned) · Start Jul 15, 2026 · Primary completion Jan 13, 2027
Drug: ZT002 injection; ZT002 injection matching placebo · For: Overweight, Obesity
Sites: Beijing, China
- A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy ParticipantsNot yet recruiting
Beijing QL Biopharmaceutical Co.,LtdIndustry
NCT07916194 · 24 participants (planned) · Start Nov 13, 2026 · Primary completion Jun 19, 2027
Drug: Zovaglutide; Zovaglutide and 1 more · For: Overweight, Obesity
Sites: Chongqing, China; Zhengzhou, China; Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
- GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies.
Zhang X, Wang T, Zhu X, et al. · Front Immunol 2023
- Circadian expression of clock and putative clock-controlled genes in skeletal muscle of the zebrafish.
Amaral IP, Johnston IA · Am J Physiol Regul Integr Comp Physiol 2012
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.